ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
Dow Jones
42.840,26
1,18%
Euro vs US Dollar
1,043
0,00%
Bitcoin
97.048,19
-0,16%
Pepperstone
Advertisement
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Supernus Pharmaceuticals Inc (SUPN) Börsenkurse

Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc (SUPN)

NASDAQ
35,43
-0,34
(-0,95%)
Geschlossen 22 Dezember 10:00PM
Verzögert um 15 Minuten
35,4305
0,0005
(0,00%)
Nach Börsenschluss: 1:59AM
Verzögert um 15 Minuten

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
35,43
Gebot
35,44
Fragen
37,33
Volumen
1.057.620
34,38 Tagesbereich 36,29
25,53 52-Wochen-Bereich 39,37
Marktkapitalisierung
1,956B
Handelsende
35,77
Handelsbeginn
35,42
Letzte Trade
86796
@
35.43
(priorref)
Letzter Handelszeitpunkt
Finanzvolumen
US$ 37.557.328
VWAP
35,5112
Durchschnittliches Volumen (3 Mio.)
334.719
Ausgegebene Aktien
55.219.273
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
1.488,66
Gewinn pro Aktie (EPS)
0,02
Erlöse
609,04M
Nettogewinn
1,32M

Über Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The company products include Oxtellar XR, Trokendi XR, SPN-812... Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The company products include Oxtellar XR, Trokendi XR, SPN-812, and others. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
www.supernus.com
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Supernus Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SUPN. The last closing price for Supernus Pharmaceuticals was US$35,77. Over the last year, Supernus Pharmaceuticals shares have traded in a share price range of US$ 25,53 to US$ 39,37.

Supernus Pharmaceuticals currently has 55.219.273 shares in issue. The market capitalisation of Supernus Pharmaceuticals is US$1,98 billion. Supernus Pharmaceuticals has a price to earnings ratio (PE ratio) of 1488.66.

SUPN Neueste Nachrichten

Weitere Nachrichten

Form 8-K - Current report

20 Dezember 2024
Edgar (US Regulatory)

Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada

MONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug...

16 Dezember 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

04 Dezember 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

03 Dezember 2024
Edgar (US Regulatory)

Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

ROCKVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment...

26 November 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 November 2024
Edgar (US Regulatory)

Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference

ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment...

13 November 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

12 November 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

12 November 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

08 November 2024
Edgar (US Regulatory)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-1.85-4.9624463519337.2837.353534529136.05110554CS
4-0.65-1.8015521064336.0837.623530577136.52451658CS
124.5814.846029173430.8539.3730.6333471935.12206879CS
268.9433.748584371526.4939.3725.550141677432.16448277CS
527.3526.175213675228.0839.3725.5342270430.86376786CS
1566.7623.578653644928.6742.0921.9941993431.66666447CS
26011.950.573735656623.5342.0913.1245752828.63868368CS

SUPN - Frequently Asked Questions (FAQ)

What is the current Supernus Pharmaceuticals share price?
The current share price of Supernus Pharmaceuticals is US$ 35,43
How many Supernus Pharmaceuticals shares are in issue?
Supernus Pharmaceuticals has 55.219.273 shares in issue
What is the market cap of Supernus Pharmaceuticals?
The market capitalisation of Supernus Pharmaceuticals is USD 1,98B
What is the 1 year trading range for Supernus Pharmaceuticals share price?
Supernus Pharmaceuticals has traded in the range of US$ 25,53 to US$ 39,37 during the past year
What is the PE ratio of Supernus Pharmaceuticals?
The price to earnings ratio of Supernus Pharmaceuticals is 1,49k
What is the cash to sales ratio of Supernus Pharmaceuticals?
The cash to sales ratio of Supernus Pharmaceuticals is 3,21
What is the reporting currency for Supernus Pharmaceuticals?
Supernus Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Supernus Pharmaceuticals?
The latest annual turnover of Supernus Pharmaceuticals is USD 609,04M
What is the latest annual profit for Supernus Pharmaceuticals?
The latest annual profit of Supernus Pharmaceuticals is USD 1,32M
What is the registered address of Supernus Pharmaceuticals?
The registered address for Supernus Pharmaceuticals is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Supernus Pharmaceuticals website address?
The website address for Supernus Pharmaceuticals is www.supernus.com
Which industry sector does Supernus Pharmaceuticals operate in?
Supernus Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
MYSZMy Size Inc
US$ 4,2001
(211,12%)
120,01M
NVNINVNI Group Ltd
US$ 8,26
(209,36%)
76,64M
TPICTPI Composites Inc
US$ 2,45
(100,82%)
33,95M
ICGIntchains Group Ltd
US$ 8,77
(88,60%)
527,61k
HSDTHelius Medical Technologies Inc
US$ 0,884851
(84,34%)
120,4M
CYNCYNGN Inc
US$ 0,4603
(-71,41%)
27,91M
MTEMMolecular Templates Inc
US$ 0,1502
(-57,09%)
8,75M
PRFXPainReform Ltd
US$ 5,15
(-53,85%)
2,94M
GALTGalectin Therapeutics Inc
US$ 1,03
(-48,50%)
9,27M
BCABBioAtla Inc
US$ 0,6923
(-41,82%)
6,25M
EDBLEdible Garden AG Inc
US$ 0,24
(65,06%)
354,33M
NVDANVIDIA Corporation
US$ 134,70
(3,08%)
310,19M
APTOAptose Biosciences Inc
US$ 0,28
(64,51%)
306,25M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,606999
(6,49%)
293,22M
PLTRPalantir Technologies Inc
US$ 80,55
(8,54%)
281,23M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
SUPN
Supernus Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten